Duo Xu

The paper identifies novel drug targets in cancer by constructing patient-specific gene regulatory networks using ATAC-seq and RNA-seq data.

The paper identifies a candidate causal variant, rs77910749, that links enhanced cognitive performance with increased bipolar disorder risk through its effect on POU3F2 expression and amygdala function.

The paper identifies LoF-tolerant enhancers in the human genome, finding they are more tissue-specific and regulate fewer genes, with predictions supported by disease enhancers and sequencing data.